| |
The pattern of resistance mutants in a population of
heavily pretreated HIV infected patients
in a resource limited setting: Implications for salvage therapy.
P Patterson, A Krolewiecki, C Ochoa, et al
Abstract
|
| |
Drug class multi-resistance as main marker of disease progression and
poor survival after
genotype-guided antiretroviral salvage therapy
M Zaccarelli, V Tozzi, P Lorenzini,, et al
Abstract
|
| |
Ritonavir boosted double protease inhibitors in salvage therapy
M Shah, C Mihailidis, E Davies,, et al
Abstract
|
| |
The LOPSAQ salvage study: 48 week analysis of the full cohort treated
with lopinavir
(LPV/r) plus saquinavir (SQV) without any additional antiretroviral
(ART) therapy
S Staszewski, B Dauer, A Carlebach, et al
Abstract
|
| |
Two non-nucleosides association as part of salvage
therapy in highly pre-treated patients.
A Guelar, H Knobel, G Vallecillo,, et al
Abstract
|
| |
The ATSAQ-1 cohort study: Pharmacokinetic interactions of atazanavir (AZV)
and
saquinavir (SQV) in a ritonavir (RTV) boosted protease inhibitor therapy
regimen
NH von Hentig, A Mueller, A Haberl, et al
Abstract |
|
XII
International HIV Drug Workshop
